SEL ICB Lambeth Community Denosumab Service

This is a Provider Selection Regime (PSR) confirmation of contract award notice. This contract has been awarded under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act 2023 do not apply to this award. This contract has now been formally awarded using direct award process C. The contract for Community Denosumab Service was awarded on 19 May 2026. The services under this contract are intended to be provided from 01 July 2026 to 30 June 2028, with the option to extend for a further 1 + 1 years at the sole discretion of the contracting authority. Should both optional extensions be exercised, the contract term will run until 30 June 2030. The total lifetime value of the contract, excluding VAT, is £2,311,995. This comprises: Year 1: £611,374 Years 2-4: £566,874 per annum The values for Years 3 and 4 are indicative and based on projected activity levels, and are subject to review and agreement prior to extension. During the standstill period, no formal review process was undertaken. The award decision was made by the following individuals: Jenny Sivaganam (Assistant Director, SEL Medicines Optimisation, NHS SEL ICB (Lambeth)) Andrew Eyres (Place Executive Lead for Lambeth and Corporate Director, Integrated Health and Adult Social Care, NHS SEL ICB) Mike Fox (Director of Finance, NHS SEL ICB) No conflicts of interest, either declared or potential, were identified in relation to the individuals involved in the decision-making process. Accordingly, no conflict management actions were required.

Organisation

NHS South East London Integrated Care Board

160 Tooley Street, London, SE1 2TZ

58

total contracts

£139.3m

total value

£10,714,111

average contract size

Pipeline status

Updated daily